Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC) Meeting Abstract
| Authors: | Choueiri, T. K.; Bedke, J.; Karam, J. A.; McKay, R. R.; Motzer, R. J.; Pal, S. M.; Suárez, C.; Uzzo, R.; Liu, H.; Burgents, J. E.; Sharma, M.; Powles, T. |
| Abstract Title: | Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC) |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.TPS748 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS748 -- Source: Cinahl |
